Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEO Presented in NYC At the JMP HealthCare Conference
Please see attached link:
http://wsw.com/webcast/jmp18/register.aspx?conf=jmp18&page=axgn.ob&url=http%3A//wsw.com/webcast/jmp18/axgn.ob/
--
Wayne Cockburn returns as CEO of iTech Medical brings BIO FLEX Merger to Table
iTech Management Updates the OTC Markets with Current Information
Great News Today, International Sales have started to Italy
Read News
Good News on bio Flex Merger opportunity look at their website www.bioflexmagnets.com
Converted to Equity will mimialzie dilution you should be happy they moved into the project
Did you See Serta New Cool Gel bed will it compete with Tempur
OSK JV with ABKI on Nano Metals Deal why does a big company do a JV with a small company must have some kind of technology. /b]
ARMY OSK AND MAJOR UNIVERSITYS WHAT IS IT GOING TO TAKE TO WAKE THIS GROUP UP
Activity on IMSU stock for past two trading days
5 million to put project under construction, i am still trying to understand structure but at least it is not diluting the shareholders
Waht Does this have to do with GDTK
Accumulating Lease JV partners + Barrells per day
Best Quarter Ever .10 Cents a Share earning
DTC was resolved, as of April 17th whatever chill that was on the stock was supposed to have been lifted.
Starr County Lease is great news more BBD
More Barrells Per Day Revenue Keeps building property portfolio means more to the bottom line
Yes Ka Ching is a good word.........
New Properties = More Revenue I can't wait to see the cash register ring
New Technology Company glass shaping for solar panels at a Fortune 500 company and begin generating a royalty stream
i emailed Eric and he called me back, he is a private funding source with corp office in clarmont attorneys office. He did say he spoke with a couple other shareholders someone named DON.
I think we should not bug him so the deal doesn't have problems
Yes Monterey CA
This financing is not a stock deal it is a private project lender that does not wish a lot of telephone calls as they share an office with an attorney in Claremont.
Also state that the 5 million line is on the monetizing of the contract for the solar project. They do not purchase stock from the company therefore dont want ot speak with shareholders
I thought it was good news but I guess it is the age old Kill the messenger or message
After Today i guess everyone has the right to bitch i just dont get it either I too have $15,000 worth of stock woth $700 bucks
I understand the frustration.
funding was Not a Stock Deal - I dont understand they got a good contract for funding the project and the stock drops
I have scottrade also my reflects but i had to call my local office FYI
Acutally you can sell your shares the DTC Chill was for buying new shares not fo rthe float. Yes last year we were working with 1st global and GDTK and i have worthless stock in one and rolled back stock in the other never sold a share in either comapny.
DTC Chill should be lifted by tomoorow Spoke to DTC
Video is really bad and shows they dont knwo how to market i almost fell a sleep, good merchandise lousy marketing makes you wonder why they would have that posted to build brand awareness
ABKI - Is anyone out there watching this company?
Oil & Gas Service Sector Videos are Great they really show what the product is all about. I think this will be a big industrial player in revamping well piping.
You have to pay the Ransom is what everyone did to land in Jail, I just want to ge t arefund for the monthly level 2 and other fees they charge me
Nite Has Stock Boxed
Note Has the stock Boxed - Need buying to knock them in the dirt then it moves to .22 and up form there llook at level 2
Selling My Shares of CTL I take all my trades as personal since it is my money. Yes have had personal bad customer service and fell for Century Links False Advertising to change the views of Quest customers
Flase Press Release Century Link does not want Business Account in the Phoneix area
WORST BUSINESS TELEPHONE SERVICE EVER.... Changing the Quest Bad Service Model is a joke! Earning will be going down if there customer service doesn't improce.
SHORT THIS STOCK
Initiates Development of Sublingual Anti-Cancer Drug, Gleevec
Kedem Pharmaceuticals Inc. (OTCBB: KDMP.OB - News), a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that has initiated the development of Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults. In children the drug has demonstrated a powerful action against Chronic Myeloid Leukemia, possibly one of the most prescribed drugs for this condition. The drug is administered orally and in children there is a significant issue in getting the drug swallowed, due to size of the pill and bad taste. Our sublingual formulation with taste masking features makes the drug acceptable and pleasant in taste for the children with chronic dosage requirements.
About Gleevec®.
Gleevec® is the registered trade name for Imatinib, a specific inhibitor of tyrosine kinase BCR-ABL. BCR-ABL is a fusion protein created by the Philadelphia Chromosome abnormality that characterizes chronic myeloid leukemia (CML). Prior to discovery of Gleevec®, the disease (CML) treatment was very unsuccessful. However, with the discovery of Gleevec®, the treatment of CML has been tremendously successful. The oral prescription dose of Gleevec®, is marketed by Novartis Pharmaceuticals.
About Kedem Pharmaceuticals Inc. KDMP.OB
A specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies. For more information visit www.kedempharmaceuticals.com
Forward-looking Statement
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release include statement within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to un foreseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities.
Completes North American Dosage Forms for X-Excite
PHOENIX, AZ--(Marketwire -01/10/12)- Kedem Pharmaceuticals Inc. (OTC.BB: KDMP.OB - News), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that has completed all the dosages production of X-Excite, the Company's lead therapeutic drug for erectile dysfunction.
Three dosages of the drug were manufactured with the final dosage forms (10, 25 and 50 mg) and appropriate labeling. The Company awaits the data from the labs on the dosages stability and disintegration studies. These studies are underway currently and once all completed, the Company can move towards the North American Clinical Trials.
"We are very pleased with the completion of dosage form and labeling, a requirement of regulatory bodies for the eventual drug approval," said Dr. Hassan Salari, Chairman and CEO of Kedem Pharmaceuticals Inc.
About X-Excite
X-Excite is a sublingual formulation of sildenafil citrate developed by Kedem Pharmaceuticals Inc. for sexual enhancement. Currently sildenafil citrate is marketed by Pfizer under the registered name Viagra®, as an oral application for erectile dysfunction.
About Kedem Pharmaceuticals Inc.
KDMP.ob is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies.
Forward-looking Statement
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release include statement within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to un foreseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities.